Monday - April 21, 2025
Sentynl Therapeutics, Inc.'s Acquisition of Zokinvy(r) Earns 2025 Distressed M&A Deal of the Year Award
February 19, 2025
NEW YORK, Feb. 19 [Category: BizLaw/Legal] -- Pillsbury, a law firm, issued the following news release:

* * *

Sentynl Therapeutics, Inc.'s Acquisition of Zokinvy(r) Earns 2025 Distressed M&A Deal of the Year Award

Pillsbury's advisement of U.S.-based biopharmaceutical company Sentynl Therapeutics, Inc. in its acquisition of Eiger Biopharmaceutical's Zokinvy(r) (lonafarnib) program was awarded Distressed M&A Deal of the Year at the 16 . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products